 Bellicum Pharmaceuticals, Inc. BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Companys common stock to David E. Strauss. The stock option was granted on January 31, 2020 with an exercise price equal to the closing price of the Companys common stock on such date. One-fourth of the shares subject to the stock option will vest on the one-year anniversary of Mr. Strauss start date and the remainder of the shares will vest in a series of 36 successive equal monthly installments thereafter. 